Objective To evaluate the efficacy of anti-Müllerian hormone(AMH), antral follicle count(AFC) and follicle-stimulating hormone(FSH) for predicting the number of oocytes retrieved in in-vitro fertilization/i...Objective To evaluate the efficacy of anti-Müllerian hormone(AMH), antral follicle count(AFC) and follicle-stimulating hormone(FSH) for predicting the number of oocytes retrieved in in-vitro fertilization/intracytoplasmic sperm injection(IVF/ICSI)cycles.Methods In this retrospective study, a total of 122 infertile women were divided into two groups: group A, 〈35 years(n=71); group B, ≥35 years(n=51). AMH and FSH were determined on 2-5 d of the early menstrual cycle. AFC was tested on the second day of the menstrual cycle before the start of stimulation.Results Group B had higher FSH levels compared with group A(8.2±3.5 IU/L vs 6.8±2.4 IU/L, P〈0.05). However, levels of AMH and AFC in group B were lower than those of group A(AMH: 4.2±3.5 μg/L vs 2.7±2.7 μg/L; AFC: 9.0±3.9 vs 5.4±3.3, P〈0.05). The number of oocyte retrieved in the two groups was not significantly different(11.5±6.8 vs 9.6±6.9, P〉0.05). The level of AMH was more strongly correlated with the number of oocytes retrieved than that of AFC or FSH level. The strengths of the correlation degrees were AMH level, AFC, and FSH level in turn(r=0.600, 0.511,-0.369).Conclusion AMH would be a useful predictor for ovarian response.展开更多
In India</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> the problem of infertility is growing and in the last 5 years</span><s...In India</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> the problem of infertility is growing and in the last 5 years</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> it has gone up to 20%</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">30%. This ongoing prospective clinical study brings forth a novel, innovative, effective, simple, affordable, easily performed outpatient procedure (OP) and a promising therapeutic method in rejuvenating the Ageing Ovaries and Thin Endometrium, with autologous Platelet Rich Plasma (PRP). This clinical study proves to give a better result in rejuvenating Ovary and treating the Thin Endometrium. This pilot study include</span><span style="font-family:Verdana;">d</span><span style="font-family:Verdana;"> five women (28</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">44 years) with Poor Ovarian Response (POR), Premature Ovarian Insufficiency (POI) and Perimenopause and Thirty-nine women (22</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">43</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">years.) with recurrent implantation failure due to Thin Endometrium were subjected to autologous PRP instillation under Ultrasound Guidance, and Hysteroscopic guided PRP. After PRP</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> a significant output was obtained, with improved Anti Mullerian Hormone (AMH) and Antral Follicle Count (AFC) and out of five women three women conceived by Intra Cytoplasmic Sperm Injection (ICSI). PRP injected in women with Poor Ovarian Response found successful ovarian rejuvenation within 1</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">3 months and had a 60% of pregnancy rate, PRP into the endometrium had 53.8% successful pregnancies. We have not encountered any complications.展开更多
文摘Objective To evaluate the efficacy of anti-Müllerian hormone(AMH), antral follicle count(AFC) and follicle-stimulating hormone(FSH) for predicting the number of oocytes retrieved in in-vitro fertilization/intracytoplasmic sperm injection(IVF/ICSI)cycles.Methods In this retrospective study, a total of 122 infertile women were divided into two groups: group A, 〈35 years(n=71); group B, ≥35 years(n=51). AMH and FSH were determined on 2-5 d of the early menstrual cycle. AFC was tested on the second day of the menstrual cycle before the start of stimulation.Results Group B had higher FSH levels compared with group A(8.2±3.5 IU/L vs 6.8±2.4 IU/L, P〈0.05). However, levels of AMH and AFC in group B were lower than those of group A(AMH: 4.2±3.5 μg/L vs 2.7±2.7 μg/L; AFC: 9.0±3.9 vs 5.4±3.3, P〈0.05). The number of oocyte retrieved in the two groups was not significantly different(11.5±6.8 vs 9.6±6.9, P〉0.05). The level of AMH was more strongly correlated with the number of oocytes retrieved than that of AFC or FSH level. The strengths of the correlation degrees were AMH level, AFC, and FSH level in turn(r=0.600, 0.511,-0.369).Conclusion AMH would be a useful predictor for ovarian response.
文摘In India</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> the problem of infertility is growing and in the last 5 years</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> it has gone up to 20%</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">30%. This ongoing prospective clinical study brings forth a novel, innovative, effective, simple, affordable, easily performed outpatient procedure (OP) and a promising therapeutic method in rejuvenating the Ageing Ovaries and Thin Endometrium, with autologous Platelet Rich Plasma (PRP). This clinical study proves to give a better result in rejuvenating Ovary and treating the Thin Endometrium. This pilot study include</span><span style="font-family:Verdana;">d</span><span style="font-family:Verdana;"> five women (28</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">44 years) with Poor Ovarian Response (POR), Premature Ovarian Insufficiency (POI) and Perimenopause and Thirty-nine women (22</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">43</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">years.) with recurrent implantation failure due to Thin Endometrium were subjected to autologous PRP instillation under Ultrasound Guidance, and Hysteroscopic guided PRP. After PRP</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> a significant output was obtained, with improved Anti Mullerian Hormone (AMH) and Antral Follicle Count (AFC) and out of five women three women conceived by Intra Cytoplasmic Sperm Injection (ICSI). PRP injected in women with Poor Ovarian Response found successful ovarian rejuvenation within 1</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-size:10pt;font-family:""> </span><span style="font-family:Verdana;">3 months and had a 60% of pregnancy rate, PRP into the endometrium had 53.8% successful pregnancies. We have not encountered any complications.